Annovis Bio Shares Are Trading Lower After the Company Announced Data From Its Phase II/III Alzheimer Study of Buntanetap in Mild to Moderate Alzheimer's. Efficacy in the CGIC Endpoint Was Not Reached Due to the Limited Number of Patients and Short Trial Duration
Annovis Bio公佈了其針對Buntanetap治療輕度至中度阿爾茨海默氏症的II/III期阿爾茨海默氏症研究的數據後，該公司股價走低。由於患者數量有限且試驗時間短，未達到CGIC終點的療效